EASL News, Press Release

New breakthrough in advanced HCC

Digital Liver Cancer Summit 2021: New follow-up data from a landmark study of liver cancer patients treated with a combination of atezolizumab and bevacizumab has shown the longest ever survival time in a frontline phase 3 trial of systemic therapy in advanced HCC demonstrating a “major breakthro…